Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma
Zhongshan People's Hospital, Guangdong, China
12,000 participants
Feb 1, 2023
OBSERVATIONAL
Conditions
Summary
All participants will be tested for EBV-related biomarkers, including EBNA1-IgA, VCA-IgA, and BNLF2b total antibody (P85-Ab), and participants with high serologic risk will be selected based on serologic test results, and dual-energy CT will be performed first for high-risk screening subjects, and dual-energy CT will be performed first for the high-risk group to record dual-energy CT examinations of those suspected of nasopharyngeal carcinoma, and then endoscopy was performed on the high-risk group to record those suspected of nasopharyngeal carcinoma under endoscopy, and finally biopsies were taken for positive lesion sites indicated by dual-energy CT and suspicious lesion sites found by endoscopy to clarify the diagnosis.
Eligibility
Inclusion Criteria4
- Subject residents in Zhongshan City
- Subject has no medical record of nasopharyngeal carcinoma
- Subject is able to comprehend, sign, and date the written informed consent document to participate in the study
- Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study
Exclusion Criteria3
- Subject has heavy cardiovascular, liver or kidney disease
- Subject has contraindications to nasopharyngeal endoscopy
- Subject has contrast media allergy
Interventions
Diagnostic Test: P85-Ab,EBNA1-IgA,and VCA-IgA. Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants and select serological high-risk participants DiagnosticTest: dual-energy CT, endoscopy and biopsy. serological high-risk participants will refer to dual-energy CT, endoscopy and biospy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05884983